Abstracts tagged "registry"

Abstract Number: 0350 • ACR Convergence 2022
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
Vicente Aldasoro¹, María Laiño¹, Monica Enguita¹, Santos Castañeda², Javier Loricera³, Carmen Lasa-Teja⁴, Clara Moriano⁵, Vanesa Calvo Río⁶, Ivette Casafont-Solé⁷, Judit Font Urgelles⁷, Patricia Quiroga-Colina⁸, Samuel Hernandez⁹, Sergi Heredia¹⁰, A. Garcia-Aparicio¹¹, Joaquin Maria Belzunegui Otano¹², Aaron Fariña¹³, Francisco Javier Navarro Blasco¹⁴, Patricia Fanlo Mateo¹, Adela Gallego¹⁵, Juan M Blanco Madrigal¹⁶, María Ángeles Matías¹⁷, Cilia Peralta¹⁸, Jordi Camins-Fàbregas¹⁹, Marcos Paulino²⁰, Ana Urruticoechea²¹, Piter Jose Cossio Jimenez²², Miguel Medina Malone²³, Eva Perez Pampin²⁴, Rafaela Ortega-Castro²⁵, Blanca varas de Dios²⁶, Jose Ramon Lamua Riazuelo²⁷ and Emilio Jose Giner²⁸, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Complejo Asistencial Universitario de León, León, Spain, ⁶Valdecilla Hospital, Santander, Spain, ⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁹Hospital Son Llàtzer, Palma de Mallorca, Spain, ¹⁰Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despi, Spain, ¹¹Hospital Universitario de Toledo, Toledo, Spain, ¹²Hospital Universitario de Donostia, Donostia-San Sebasti, Spain, ¹³Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Hospital General Universitario de Elche, Elche, Spain, ¹⁵Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹⁶Basurto University Hospital, Bilbao, Spain, ¹⁷Hospital Universitario Infanta Leonor, Madrid, Spain, ¹⁸Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁹Hospital General de Granollers, Granollers, Spain, ²⁰Hospital General Universiario de Ciudad Real, Ciudad Real, Spain, ²¹Hospital Can Misses, Ibiza, Spain, ²²Hospital Reina Sofia, Tudela, Spain, ²³Hospital Calahorra, Calahorra, Spain, ²⁴Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, ²⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²⁶Santa Cristina Hospital, Madrid, Spain, ²⁷Hospital Universitario del Henares, Madrid, Spain, ²⁸Hospital Royo Villanova, Zaragoza, Spain
Background/Purpose: To describe demographic characteristics, efficacy and safety of BLM since its approval in SLE patients in a real-world setting. Methods: Descriptive, retrospective, multicenter study…
Abstract Number: 1431 • ACR Convergence 2022
Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis
Karen E Hansen¹, Mahta Mortezavi², Edward Nagy³, Cunshan Wang⁴, Carol A Connell⁴, Zaher Radi⁵, Heather J Litman⁶, Giovanni Adami⁷ and Maurizio Rossini⁷, ¹Rheumatology Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Pfizer Inc, New York, NY, ³Pfizer Ltd, Tadworth, United Kingdom, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Preclinical data suggest that tofacitinib stimulates osteoblast function and would have a protective effect on bone health and fracture risk in RA.1 We report…
Abstract Number: 0422 • ACR Convergence 2022
Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort
Semih Gulle¹, Ali Karakas¹, Gercek Can², Soner Senel³, Sedat Capar⁴, Huseyin ediz dalkilic⁵, Servet Akar⁶, Suleyman Serdar Koca⁷, Abdurrahman Tufan⁸, Ayten Yazici⁹, Sema Yilmaz¹⁰, Nevsun Inanc¹¹, Merih Birlik¹, Dilek Solmaz¹², Ayse Cefle⁹, Berna Goker¹³, Servet Yolbas¹⁴, Niels Steen Krough¹⁵, Neslihan Yilmaz¹⁶, Sukran Erten¹⁷, Cemal Bes¹⁸, Ozgul Soysal¹⁹, Mehmet Akif Ozturk¹³, Seminur Haznedaroglu¹³, Sule Yavuz¹⁶, Haner Direskeneli²⁰, Fatoş Onen²¹ and Ismail Sari²², ¹Dokuz Eylul University School of Medicine Division of Rheumatology, Izmir, Turkey, ²Dokuz Eylul University School of Medicine Division of Rheumatology, Istanbul, Turkey, ³Erciyes University School of Medicine Division of Rheumatology, Kayseri, Turkey, ⁴Dokuz Eylul University Faculty of Science Department of Statistics, Izmir, Turkey, ⁵Uludag University School of Medicine Division of Rheumatology, Bursa, Turkey, ⁶Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁷Firat University School of Medicine Division of Rheumatology, Elazıg, Turkey, ⁸Gazi University Medical Faculty Hospital, Istanbul, Turkey, ⁹Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, ¹⁰Selcuk University School of Medicine Division of Rheumatology, Konya, Turkey, ¹¹Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, ¹²Kâtip Celebi University School of Medicine Division of Rheumatology, Izmir, Turkey, ¹³Gazi University School of Medicine Division of Rheumatology, Ankara, Turkey, ¹⁴Inonu University School of Medicine Division of Rheumatology, Malatya, Turkey, ¹⁵Zitelab Aps, Kopenhag, Denmark, ¹⁶Demiroglu Bilim University School of Medicine Division of Rheumatology, Istanbul, Turkey, ¹⁷Yildirim Beyazit University School of Medicine Division of Rheumatology, Ankara, Turkey, ¹⁸Basaksehir Cam and Sakura ospital, Division of Rheumatology, Istanbul, Turkey, ¹⁹Celal Bayar University, School of Medicine Division of Rheumatology, Manisa, Turkey, ²⁰Marmara University School of Medicine Division of Rheumatology, Istanbul, Turkey, ²¹Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, ²²Dokuz Eylul University School of Medicine Division of Rheumatology, İzmir, Turkey
Background/Purpose: In this study, we aimed to evaluate the results of secukinumab treatment in patients with Axial Spondyloarthritis (AxSpA) who were enrolled in the TURKBIO…
Abstract Number: 1522 • ACR Convergence 2022
The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Medication Use on Gastrointestinal Tract Symptoms in Early Disease
Sarah Luebker¹, Tracy Frech¹, Shervin Assassi², Jessica Gordon³, Elana Bernstein⁴, Virginia Steen⁵, Ami Shah⁶, Laura Hummers⁷, Carrie Richardson⁸, Dinesh Khanna⁹, Flavia Castelino¹⁰, Lorinda Chung¹¹, Faye Hant¹², Vicki Shanmugam¹³, John VanBuren¹⁴, Jessica Alvey¹⁴, Monica Harding¹⁴, Luke Evnin¹⁵ and Nora Sandorfi¹⁶, ¹Vanderbilt University Medical Center, Nashville, TN, ²McGovern Medical School, University of Texas, Houston, TX, ³Hospital for Special Surgery, New York, NY, ⁴Columbia University, New York, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Johns Hopkins Rheumatology, Baltimore, MD, ⁷Johns Hopkins Univerisity, Baltimore, MD, ⁸Northwestern University, Chicago, IL, ⁹Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹Stanford University, Stanford, CA, ¹²Medical University of South Carolina, Charleston, SC, ¹³George Washington University, Washington, DC, ¹⁴University of Utah, Salt Lake City, UT, ¹⁵Scleroderma Research Foundation, Brisbane, CA, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Gastrointestinal tract (GIT) symptoms are common amongst systemic sclerosis (SSc) patients.1 The Scleroderma Clinical Trials Consortium University of California Los Angeles Gastrointestinal Tract Questionnaire…
Abstract Number: 0433 • ACR Convergence 2022
Clustering of Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis – Using a Pre-processed Harmonised Dataset
Karl Gisslander¹, Arthur White², Mårten Segelmark³, Mark Little² and Aladdin Mohammad⁴, ¹Lund University, Lund, Sweden, ²Trinity College, Dublin, Ireland, ³Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: The sub-classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been a long-standing debate. Unsupervised learning has previously been used for partitioning of phenotypic…
Abstract Number: 1679 • ACR Convergence 2022
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, MaryEllen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Mei Sing Ong¹¹ and Marc Natter¹², ¹Hackensack Meridian Health, New York, NY, ²Janssen, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack Meridian Health, Hackensack, NJ, ⁷CARRA, Inc, Washington, DC, ⁸CARRA, Inc, New Orleans, LA, ⁹Children's Hospital of Philadelphia, Glen Mills, PA, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹¹Harvard Pilgrim Institute, Boston, MA, ¹²Boston Children's Hospital, Boston, MA
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: 0820 • ACR Convergence 2022
Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study
Diala Alawneh¹, Moustafa Younis², Bashar Alzghoul², Christian Ascoli¹, Tricha Shivas³, Mary McGowan³, Khaldoon Alawneh⁴, Divya Patel², Israel Rubinstein¹ and Nadera Sweiss¹, ¹University of Illinois at Chicago, Chicago, IL, ²University of Florida, Gainesville, FL, ³Foundation for Sarcoidosis Research, Chicago, IL, ⁴Jordan University of Science and Technology, Irbid, Jordan
Background/Purpose: Chronic arthropathy is a rare manifestation of sarcoidosis reported in only 0.2% of patients. However, treatment is challenging because no general consensus regarding appropriate…
Abstract Number: 1752 • ACR Convergence 2022
Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER
Isabel Castrejon¹, Juan Molina², Carolina Perez-Garcia³, Paloma Vela-Casampere⁴, Cesar Diaz-Torne⁵, Cristina Bohorquez⁶, Juan Maria Blanco-Madrigal⁷ and Fernando Sanchez-Alonso⁸, ¹Hospital Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Department of Rheumatology, Hospital del Mar, Barcelona, Spain, ⁴Hospital General Universitario Alicante, Alicante, Spain, ⁵Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, ⁷Department of Rheumatology, Hospital de Basurto, Bilbao, Spain, ⁸Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
Background/Purpose: Extensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk…
Abstract Number: 0850 • ACR Convergence 2022
Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Shahla Amin², Stephen Balevic³, Colleen Correll⁴, Timothy Beukelman¹ and , for the CARRA Registry Investigators⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Childhood Arthritis and Rheumatology Research Alliance, Washington, DC, ³Duke University, Durham, NC, ⁴University of Minnesota, Minneapolis, MN, ⁵CARRA, Washington, DC
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are the most commonly used first biologics to treat juvenile idiopathic arthritis (JIA), but it is unknown what subsequent…
Abstract Number: 1842 • ACR Convergence 2022
Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry
Jasmin B. Kuemmerle-Deschner¹, Joerg Henes², Birgit Kortus-Goetze³, Tilmann Kallinich⁴, Prasad T. Oommen⁵, Juergen Rech⁶, Tobias Krickau⁷, Frank Weller-Heinemann⁸, Gerd Horneff⁹, Ales Janda¹⁰, Ivan Foeldvari¹¹, Catharina Schuetz¹², Frank Dressler¹³, Michael Borte¹⁴, Markus Hufnagel¹⁵, Florian Meier¹⁶, Michael Fiene¹⁷, Julia Weber-Arden¹⁸ and Norbert Blank¹⁹, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, ²Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ³Division of Nephrology, University of Marburg, Marburg, Germany, ⁴Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁵Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁶University Clinic Erlangen, Erlangen, Germany, ⁷Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, ⁸Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ⁹Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ¹⁰Department of Pediatrics, University Hospital Ulm, Ulm, Germany, ¹¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ¹²Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, ¹³Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ¹⁴ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, ¹⁵Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹⁶Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ¹⁷Rheumatology Center Greifswald, Greifswald, Germany, ¹⁸Novartis Pharma GmbH, Nuernberg, Germany, ¹⁹Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Treatment of autoinflammatory periodic syndromes with the interleukin-1β inhibitor canakinumab (CAN) has been shown to be safe and effective in clinical trials and in…
Abstract Number: 0855 • ACR Convergence 2022
Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Fenglong Xie¹, Timothy Beukelman¹, Jeffrey Curtis² and , for the CARRA Registry Investigators³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Hoover, AL, ³CARRA, Washington, DC
Background/Purpose: Current recommendations suggest treatment escalation for juvenile idiopathic arthritis (JIA) until the disease activity target is reached, ideally inactive or low disease activity. Our…
Abstract Number: 1992 • ACR Convergence 2022
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Page Moore³, Elizabeth Kohl³, Bernice Gershenson³, Oksana Pugach³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
Abstract Number: 0888 • ACR Convergence 2022
Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)
Nathalie Carrier¹, Sophie Roux², Hugues Allard-Chamard² and Gilles Boire³, ¹Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ²Université de Sherbrooke and Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ³Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Uncontrolled inflammation in rheumatoid arthritis (RA) patients increases the risk for incident Ischemic Heart Disease (IHD) and venous thromboembolic (TE) events. Reducing inflammation using…
Abstract Number: 1999 • ACR Convergence 2022
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Vibeke Strand¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹Stanford University School of Medicine, Stanford, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
Abstract Number: 0950 • ACR Convergence 2022
Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry
Sinead Maguire¹, Samar Al emadi², Paul Alba³, Mathia C Aguiar⁴, Talal Al Lawati⁵, Gelsomina Alle⁶, Bonnie Bermas⁷, Suleman Bhana⁸, Branimir Anic⁹, Inita Bulina¹⁰, Megan Clowse¹¹, Adriana Karina Cogo¹², Iris Colunga¹³, Claire Cook¹⁴, KAREN JOYCE CORTEZ¹⁵, Kathryn Dao¹⁶, Milena Gianfrancesco¹⁷, Monique Gore-Massy¹⁸, Laure Gossec¹⁹, Rebecca Grainger²⁰, Jonathan Hausmann²¹, Tiffany YT Hsu²², Kimme Hyrich²³, Carolina Isnardi²⁴, Yumeko Kawano²², Rachael Kilding²⁵, Daria A Kusevich²⁶, Saskia Lawson-Tovey²⁷, Jean Liew²⁸, Eoghan McCarthy²⁹, Anna Montgomery³⁰, Sebastian Moyano³, Noreen Nasir³¹, IVAN PADJEN³², Charalampos Papagoras³³, Naomi Patel³⁴, MARIANA PERA³⁵, Cecilia Pisoni³⁶, Guillermo Pons-Estel³⁷, Antonio Lorenzo Quiambao³⁸, Rosana Quintana³⁹, Eric Ruderman⁴⁰, Sebastian Sattui⁴¹, Veronica Savio⁴², Savino Sciascia⁴³, Marieta Sencarova⁴⁴, Rosa Serrano-Morales⁴⁵, Faizah Siddique⁴⁶, Emily Sirotich⁴⁷, Jeffrey Sparks⁴⁸, Anja Strangfeld⁴⁹, Paul Sufka⁵⁰, Helen Tanner⁵¹, Yohana Tissera⁵², Zachary Wallace¹⁴, Marina Werner⁵³, Leanna Wise⁵⁴, Angus Worthing⁵⁵, JoAnn Zell⁵⁶, Julija Zepa¹⁰, Pedro Machado⁵⁷, Jinoos Yazdany¹⁷, Philip Robinson⁵¹ and Richard Conway¹,¹St James' Hospital, Dublin, Ireland, ²Hamad Medical Corporation, Doha, Qatar, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital General Agustin O`Horan, Merida, Mexico, ⁵Sultan Qaboos University Hospital, Muscat, Oman, ⁶Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷UT Southwestern, Dallas, TX, ⁸Crystal Run Healthcare, Middletown, NY, ⁹Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, ¹⁰Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, ¹¹Duke University, Durham, NC, ¹²Hospital Interzonal Luis Guemes, Haedo and Hospital San Juan de Dios, Castelar, Buenos Aires, Argentina, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Massachusetts General Hospital, Boston, MA, ¹⁵Baguio General Hospital Medical Center, Baguio, Philippines, ¹⁶UT Southwestern Medical Center, Dallas, TX, ¹⁷University of California San Francisco, San Francisco, CA, ¹⁸Covid-19 GRA, West Orange, NJ, ¹⁹Sorbonne Université, Paris, France, ²⁰University of Otago, Wellington, New Zealand, ²¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²²Brigham and Women's Hospital, Boston, MA, ²³The University of Manchester, Manchester, United Kingdom, ²⁴SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ²⁵Sheffield teaching hospitals trust, Sheffield, United Kingdom, ²⁶VA Nasonova Research Institute of Rheumatology, Moscow and Anikina Clinic, Vidnoe, Russia, ²⁷Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²⁸Boston University, Boston, MA, ²⁹Beaumont Hospital, Dublin, Ireland, ³⁰University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, ³¹Aga Khan University Hospital, Karachi Pakistan, Karachi, Pakistan, ³²University Hospital Center Zagreb, Zagreb, Croatia, ³³First Department of Internal Medicine and Laboratory of Molecular Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ³⁴Massachusetts General Hospital, Sale Creek, TN, ³⁵Hospital Ángel C Padilla, San Miguel de Tucumán, Tucuman, Argentina, ³⁶CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ³⁷Argentine Society of Rheumatology, Buenos Aires, Argentina, ³⁸East Avenue Medical Center, Quezon City, Philippines, ³⁹Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁴⁰Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴¹University of Pittsburg, Pittsburg, Pennsylvania, USA, PIttsburgh, PA, ⁴²Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, ⁴³University of Turin, Torino, Italy, ⁴⁴Univerzitna nemocnica L Pasteura, Slovakia, Kosice, Slovakia, ⁴⁵Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumáticas del Grupo Oroño, Rosario, Argentina, ⁴⁶Loyola University Medical Center, Elmhurst, IL, ⁴⁷Department of Health Research, Evidence and Impact, McMaster University, Hamilton, ON, Canada, ⁴⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴⁹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁵⁰HealthPartners, Eagan, MN,⁵¹University of Queensland School of Medicine, Brisbane, Queensland, Australia, ⁵²Internal Medicine Service, Rheumatology Unit, Hospital Córdoba y Sanatorio Parque de Córdoba, Córdoba, Argentina, ⁵³Hospital Nacional de Clínicas, Córdoba, Argentina, ⁵⁴LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁵⁵Arthritis & Rheumatism Associates, PC, Washington, DC, ⁵⁶University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London and National Institute for Health Research (NIHR), University College London Hospitals NHS Foundation Trust, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
Background/Purpose: To describe obstetric outcomes based on COVID-19 vaccination status in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.Methods: We extracted…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].